Maurizio Zangari

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
  2. ncbi Impact of bortezomib on bone health in myeloma: a review of current evidence
    Maurizio Zangari
    Stem Cell Transplant and Myeloma Program, University of Utah, UT 84132, USA
    Cancer Treat Rev 38:968-80. 2012
  3. ncbi Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens
    Maurizio Zangari
    Blood Marrow Transplant and Myeloma Program, Division of Hematology, University of Utah, Salt Lake City, UT 84132, USA
    Clin Lymphoma Myeloma Leuk 11:228-36. 2011
  4. ncbi Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls
    Maurizio Zangari
    Myeloma Program, Division of Hematology, University of Utah, Salt Lake City, Utah, USA
    Blood Coagul Fibrinolysis 22:420-3. 2011
  5. ncbi Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
    Maurizio Zangari
    Division of Hematology, University of Utah, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
    Eur J Haematol 86:484-7. 2011
  6. ncbi A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
    Maurizio Zangari
    University of Utah, Salt Lake City, Utah, USA
    Haematologica 96:333-6. 2011
  7. ncbi Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone
    Maurizio Zangari
    Division of Hematology, Blood Marrow Transplant and Myeloma Program, 30 N 1900 E, 5C402, University of Utah, Salt Lake City, UT 84132, USA
    J Clin Oncol 28:132-5. 2010
  8. ncbi Thrombotic events in patients with cancer receiving antiangiogenesis agents
    Maurizio Zangari
    University of Utah, Division of Hematology, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
    J Clin Oncol 27:4865-73. 2009
  9. ncbi Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation
    Jong Hun Kim
    Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, Utah 84132, USA
    Biol Blood Marrow Transplant 18:1753-8. 2012
  10. ncbi NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers
    Wen Zhou
    Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
    Cancer Cell 23:48-62. 2013

Detail Information

Publications16

  1. ncbi Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
    ..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
  2. ncbi Impact of bortezomib on bone health in myeloma: a review of current evidence
    Maurizio Zangari
    Stem Cell Transplant and Myeloma Program, University of Utah, UT 84132, USA
    Cancer Treat Rev 38:968-80. 2012
    ..As reviewed here, a growing body of evidence indicates that bortezomib exerts a positive effect on bone metabolism in MM and has a bone anabolic effect...
  3. ncbi Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens
    Maurizio Zangari
    Blood Marrow Transplant and Myeloma Program, Division of Hematology, University of Utah, Salt Lake City, UT 84132, USA
    Clin Lymphoma Myeloma Leuk 11:228-36. 2011
    ..Taken together, these data confirm the low VTE risk associated with bortezomib and support a potential protective effect of bortezomib in combination with IMiD-based regimens associated with elevated VTE risk...
  4. ncbi Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls
    Maurizio Zangari
    Myeloma Program, Division of Hematology, University of Utah, Salt Lake City, Utah, USA
    Blood Coagul Fibrinolysis 22:420-3. 2011
    ..045) serum levels and a direct correlation with prothrombin time value (P=0.034). The Pefakit APC-R test measured as continuous variable shows a statistically significant decrease in patients with myeloma compared to normal individuals...
  5. ncbi Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
    Maurizio Zangari
    Division of Hematology, University of Utah, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
    Eur J Haematol 86:484-7. 2011
    ..This retrospective analysis of patients with relapsed or refractory myeloma treated with single-agent carfilzomib indicates that early elevation in ALP is associated with subsequent myeloma response...
  6. ncbi A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
    Maurizio Zangari
    University of Utah, Salt Lake City, Utah, USA
    Haematologica 96:333-6. 2011
    ..04 on days 11, 21, 33) in responding individuals. This study demonstrates that the myeloma control produced by proteasome inhibition is associated with bone changes and to a discrete pattern of hormonal variation...
  7. ncbi Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone
    Maurizio Zangari
    Division of Hematology, Blood Marrow Transplant and Myeloma Program, 30 N 1900 E, 5C402, University of Utah, Salt Lake City, UT 84132, USA
    J Clin Oncol 28:132-5. 2010
    ..7, time to progression P = .1). CONCLUSION Patients with MM treated with lenalidomide and high-dose dexamethasone who developed a VTE did not experience shorter overall survival or time to progression...
  8. ncbi Thrombotic events in patients with cancer receiving antiangiogenesis agents
    Maurizio Zangari
    University of Utah, Division of Hematology, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
    J Clin Oncol 27:4865-73. 2009
    ..Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy...
  9. ncbi Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation
    Jong Hun Kim
    Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, Utah 84132, USA
    Biol Blood Marrow Transplant 18:1753-8. 2012
    ..CMV surveillance should be considered, especially when tandem transplantation is performed using combination chemotherapy with high-dose melphalan...
  10. ncbi NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers
    Wen Zhou
    Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
    Cancer Cell 23:48-62. 2013
    ..High expression of NEK2 induced drug resistance mainly through activation of the efflux pumps. Thus, NEK2 represents a strong predictor for drug resistance and poor prognosis in cancer and could be an important target for cancer therapy...
  11. ncbi Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs
    Maurizio Zangari
    Myeloma Program, Division of Hematology, University of Utah, Salt Lake City, Utah
    Semin Thromb Hemost 38:768-79. 2012
    ..In this review we will focus on IMiD-associated effects on specific thrombotic mechanisms...
  12. ncbi Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
    Lei Shi
    Division of Hematology BMT myeloma Program, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Oncotarget 1:22-33. 2010
    ..Thus, our findings provide a rationale for targeting STAT3 and MEK/ERK/BCL2 signaling in aggressive CKS1B-overexpressing MM...
  13. ncbi Low-risk identification in multiple myeloma using a new 14-gene model
    Tiehua Chen
    Molecular Medicine Program, University of Utah, Salt Lake City, Utah 84132, USA
    Eur J Haematol 89:28-36. 2012
    ..We have developed a new gene model (MMSI14) for defining low-risk, newly diagnosed MM. The multivariate comparative analysis confirmed that MMSI14 is the best available model to predict clinical outcome in MM patients...
  14. ncbi Bone and paraproteinemias
    Maurizio Zangari
    University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Curr Opin Support Palliat Care 4:195-9. 2010
    ..Bone has always been considered a target organ for neoplastic disorder. This review analyzed the close interaction between bone microenvironment and paraproteinemias...
  15. ncbi Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?
    Maurizio Zangari
    Division of Hematology, University of Utah, Salt Lake City, UT 84132, USA
    Blood Coagul Fibrinolysis 24:311-6. 2013
    ..This retrospective study suggests that even moderate hypoxia associated with 5000 feet elevation should be considered as an independent prothrombotic risk factor. This observation needs to be confirmed by prospective studies...
  16. ncbi Progress in myeloma stem cells
    Richard Dela Cruz
    Division of Hematology, Blood Marrow Transplant and Myeloma Program 30 N 1900 E, 5C417, University of Utah, Salt Lake City, UT 84132, USA
    Am J Blood Res 1:135-45. 2011
    ..In this review, we report recent progress of cell surface markers in cancer stem cells, especially in myeloma and the molecular mechanisms related to drug resistance and myeloma disease progression...